Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Casgevy becomes first CRISPR drug to get approval
by Laura Howes
November 23, 2023
| A version of this story appeared in
Volume 101, Issue 39
Casgevy, Vertex Pharmaceuticals and CRISPR Therapeutics’ drug to treat sickle cell disease and β-thalassemia, has become the first CRISPR-based medicine in the world to be approved. The UK Medicines and Healthcare Products Regulatory Agency approved Casgevy for patients on Nov. 16; US and European regulators are still considering the drug for approval. Casgevy works by editing blood stem cells to restart making fetal hemoglobin. Clinical trials have shown this dramatically improves the lives of people with either condition.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter